Cover Image
市場調查報告書

歐洲肺癌治療藥的開發平台分析

Europe Lung Cancer Drug Pipeline Analysis

出版商 PNS Pharma 商品編碼 302554
出版日期 內容資訊 英文 340 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
歐洲肺癌治療藥的開發平台分析 Europe Lung Cancer Drug Pipeline Analysis
出版日期: 2014年01月14日 內容資訊: 英文 340 Pages
簡介

肺癌是在罹患率與死亡率中最常見的癌症。肺癌主要有小細胞癌及非小細胞癌(NSCLC)二種,各佔肺癌市場整體約20%與80%。80%肺癌發症的原因是抽煙,其他原因則有過度使用石棉及過度曝露於氡氣下。

本報告詳細調查在歐洲正在開發的各種肺癌治療藥,為您概述為以下內容。

第1章 歐洲的肺癌市場概要

第2章 臨床開發階段的肺癌治療藥:不明

  • 概要
  • 開發階段的肺癌治療藥簡介

第3章 臨床開發階段的肺癌治療藥:臨床試驗前

  • 概要
  • 開發階段的肺癌治療藥簡介

第4章 臨床開發階段的肺癌治療藥:臨床試驗

  • 概要
  • 開發階段的肺癌治療藥簡介

第5章 臨床開發階段的肺癌治療藥:階段I

  • 概要
  • 開發階段的肺癌治療藥簡介

第6章 臨床開發階段的肺癌治療藥:階段I/II

  • 概要
  • 開發階段的肺癌治療藥簡介

第7章 臨床開發階段的肺癌治療藥:階段II

  • 概要
  • 開發階段的肺癌治療藥簡介

第8章 臨床開發階段的肺癌治療藥:階段II/III

  • 概要
  • 開發階段的肺癌治療藥簡介

第9章 臨床開發階段的肺癌治療藥:階段III

  • 概要
  • 開發階段的肺癌治療藥簡介

第10章 臨床開發階段的肺癌治療藥:預備登記

  • 概要
  • 開發階段的肺癌治療藥簡介

第11章 臨床開發階段的肺癌治療藥:登記完畢

  • 概要
  • 開發階段的肺癌治療藥簡介

第12章 上市

  • 概要
  • 已上市肺癌治療藥簡介
目錄

The most common type of cancer in terms of incidence and mortality rate is Lung cancer. Lung cancer is a disease in which the lining of the cell of the lung tissue has an uncontrollable growth which in turn leads to the formation of tumor. There are two main types of lung cancer; small cell lung cancer which accounts for about 20% and non-small cell lung cancer (NSCLC) that accounts for about 80% of the total lung cancers. The major cause for around 80% of all lung cancers is the use of tobacco. Other causes include excessive usage of asbestos and high exposure to radon gas. In Europe, while around one quarter of cancer patients are more than 70 years old, and are largely affected by colorectal, gastric and prostate cancer, the younger population is observed to be more affected by lung cancer, along with brain and kidney cancer.

"Europe Lung Cancer Drug Pipeline Analysis" by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of lung cancer in Europe. Research report covers all drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Europe lung cancer drug market based upon development process.

Following parameters for each drug profile in development phase are covered in "Europe Lung Cancer Drug Pipeline Analysis" research report:

  • Drug Profile Overview
  • Alternate Names for Drug
  • Active Indication
  • Phase of Development
  • Mechanism of Action
  • Brand Name
  • Patent Information
  • Orphan Designation by Indication, Country & Organisation
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class *

ATC Codes

Number of Lung Cancer Drugs in Pipeline by Clinical Phase:

  • Preclinical: 7
  • Clinical: 4
  • Phase-I: 11
  • Phase-I/II: 13
  • Phase-II: 56
  • Phase-II/III: 3
  • Phase-III: 28
  • Preregistration:2
  • Registered: 1
  • Marketed: 13
  • Unknown: 1

Table of Contents

1. Europe Lung Cancer Drug Market Overview

2. Lung Cancer Drug Clinical Development Phase: Unknown

  • 2.1. Overview
  • 2.2. Lung Cancer Drug Profile in Development Phase

3. Lung Cancer Drug Clinical Development Phase: Preclinical

  • 3.1. Overview
  • 3.2. Lung Cancer Drug Profile in Development Phase

4. Lung Cancer Drug Clinical Development Phase: Clinical

  • 4.1. Overview
  • 4.2. Lung Cancer Drug Profile in Development Phase

5. Lung Cancer Drug Clinical Development Phase: Phase-I

  • 5.1. Overview
  • 5.2. Lung Cancer Drug Profile in Development Phase

6. Lung Cancer Drug Clinical Development Phase: Phase-I/II

  • 6.1. Overview
  • 6.2. Lung Cancer Drug Profile in Development Phase

7. Lung Cancer Drug Clinical Development Phase: Phase-II

  • 7.1. Overview
  • 7.2. Lung Cancer Drug Profile in Development Phase

8. Lung Cancer Drug Clinical Development Phase: Phase-II/III

  • 8.1. Overview
  • 8.2. Lung Cancer Drug Profile in Development Phase

9. Lung Cancer Drug Clinical Development Phase: Phase-III

  • 9.1. Overview
  • 9.2. Lung Cancer Drug Profile in Development Phase

10. Lung Cancer Drug Clinical Development Phase: Preregistration

  • 10.1. Overview
  • 10.2. Lung Cancer Drug Profile in Development Phase

11. Lung Cancer Drug Clinical Development Phase: Registered

  • 11.1. Overview
  • 11.2. Lung Cancer Drug Profile in Development Phase

12. Marketed

  • 12.1. Overview
  • 12.2. Marketed Lung Cancer Drug Profile

List of Table

Each Drug Profile has Tables Representing Following Information:

  • Alternate Names
  • Originator & Owner
  • Collaborator
  • Technology Provider
  • Licensee
  • Highest Development Phase
  • Indications
  • Class
  • Mechanism of Action
  • ATC Code
  • Designated Brand Name
Back to Top